News headlines about Nymox Pharmaceutical Corporation (NASDAQ:NYMX) have trended positive recently, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nymox Pharmaceutical Corporation earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.1329699386942 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have effected Accern’s rankings:
- Commit To Buy Nymox Pharmaceutical Corp At $3, Earn 33.3% Using Options (stockoptionschannel.com)
- Short Interest Falls 63.6% For NYMX (thestreet.com)
- Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional … (globenewswire.com)
- Nymox Pharmaceutical Corporation (NYMX) is at $3.77 per share and Mesa Laboratories, Inc. (MLAB) is listed at $151.99 – Stocks Gallery (stocksgallery.com)
- Nymox Pharmaceutical Corporatio (NASDAQ:NYMX) Experiences … – First News 24 (firstnewspaper24.com)
Shares of Nymox Pharmaceutical Corporation (NYMX) traded down 2.22% during trading on Friday, hitting $3.97. The company’s stock had a trading volume of 66,118 shares. The company has a 50-day moving average price of $3.82 and a 200-day moving average price of $3.93. The stock’s market cap is $207.90 million. Nymox Pharmaceutical Corporation has a one year low of $2.67 and a one year high of $5.10.
Separately, ValuEngine cut Nymox Pharmaceutical Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, June 27th.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://sportsperspectives.com/2017/10/13/positive-press-coverage-somewhat-unlikely-to-affect-nymox-pharmaceutical-corporation-nymx-stock-price.html.
In other news, Director James George Robinson purchased 10,000 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The shares were acquired at an average price of $3.73 per share, with a total value of $37,300.00. Following the purchase, the director now directly owns 3,077,550 shares of the company’s stock, valued at $11,479,261.50. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have bought a total of 30,000 shares of company stock worth $112,050 in the last three months. Corporate insiders own 54.00% of the company’s stock.
Nymox Pharmaceutical Corporation Company Profile
Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.
Receive News & Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related companies with MarketBeat.com's FREE daily email newsletter.